{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461769932
| IUPAC_name = 5-oxo-<small>L</small>-prolyl-<small>L</small>-histidyl-<small>L</small>-tryptophyl-<small>L</small>-seryl-<small>L</small>-tyrosyl-1-benzyl-<small>D</small>-histidyl-<small>L</small>-leucyl-''N''<sup>5</sup>-(diaminomethylene)-<small>L</small>-ornithyl-''N''-ethyl-<small>L</small>-prolinamide
| image = Histrelin.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|histrelin}}
| MedlinePlus = a601146
| pregnancy_US = X
| legal_US = Rx-only
| routes_of_administration = Subcutaneous [[Implant (medicine)|implant]]

<!--Pharmacokinetic data-->
| bioavailability = 92%
| protein_bound = 70%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 4.0 hours
| excretion = Undetermined

<!--Identifiers-->
| IUPHAR_ligand = 3884
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 76712-82-8
| ATC_prefix = L02
| ATC_suffix = AE05
| PubChem = 25077993
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482012
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = H50H3S3W74
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02369
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201255

<!--Chemical data-->
| C=66 | H=86 | N=18 | O=12 
| molecular_weight = 1323.5 g/mol
| smiles = CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@@H]8CCC(=O)N8
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C66H86N18O12/c1-4-70-64(95)55-17-11-25-84(55)65(96)48(16-10-24-71-66(67)68)76-58(89)49(26-38(2)3)77-62(93)53(30-43-34-83(37-74-43)33-40-12-6-5-7-13-40)81-59(90)50(27-39-18-20-44(86)21-19-39)78-63(94)54(35-85)82-60(91)51(28-41-31-72-46-15-9-8-14-45(41)46)79-61(92)52(29-42-32-69-36-73-42)80-57(88)47-22-23-56(87)75-47/h5-9,12-15,18-21,31-32,34,36-38,47-55,72,85-86H,4,10-11,16-17,22-30,33,35H2,1-3H3,(H,69,73)(H,70,95)(H,75,87)(H,76,89)(H,77,93)(H,78,94)(H,79,92)(H,80,88)(H,81,90)(H,82,91)(H4,67,68,71)/t47-,48-,49-,50-,51-,52-,53+,54-,55-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HHXHVIJIIXKSOE-QILQGKCVSA-N
}}
'''Histrelin''' acetate is a nonapeptide analog of [[gonadotropin-releasing hormone]] (GnRH) with added potency.<ref name="def">[http://uuhsc.utah.edu/pharmacy/bulletins/histrelin.html Histrelin acetate (Vantas)] - New Drug Bulletins</ref> When present in the bloodstream, it acts on particular cells of the [[pituitary gland]] called [[gonadotrope]]s. Histrelin stimulates these cells to release [[luteinizing hormone]] and [[follicle-stimulating hormone]]. Thus it is considered a [[gonadotropin-releasing hormone agonist]] or GnRH [[agonist]].

Histrelin is marketed by Endo Pharmaceuticals under the brand names '''Vantas''' and '''Supprelin LA'''.

==Medical uses==
Histrelin is used to treat hormone-sensitive cancers of the [[prostate cancer|prostate]] in men and [[uterine fibroids]] in women. In addition, histrelin has been proven to be highly effective in treating central [[precocious puberty]] in children.<ref>[http://www.drugs.com/cons/Histrelin.html Histrelin consumer information]</ref><ref>{{cite journal | last = Eugster  | first = Erica A. |author2=William Clarke | title = Efficacy and Safety of Histrelin Subdermal Implant in Children with Central Precocious Puberty: A Multicenter Trial | journal = J Clin Endocrinol Metab | volume = 92 | issue = 5 | pages = 1697&ndash;1704 | publisher = | date = 2007 | url = http://jcem.endojournals.org/cgi/content/abstract/92/5/1697 | doi = 10.1210/jc.2006-2479 | id = | accessdate = 2007-10-17 | pmid = 17327379 |display-authors=etal}}</ref>

It is available as a daily intramuscular injection. 

Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer, since 2005 in the US, and since Jan 2010 in the UK.<ref>{{cite news|title=Implant inserted under the skin ends the misery of prostate jabs|url=http://www.dailymail.co.uk/health/article-1263830/Implant-ends-misery-prostate-jabs.html|work=Daily Mail|date=6 April 2010|archiveurl=https://web.archive.org/web/20120623075613/http://www.dailymail.co.uk/health/article-1263830/Implant-ends-misery-prostate-jabs.html|archivedate=2012-06-23|page=48|dead-url=no}}</ref>

A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. [[Food and Drug Administration]].

Histrelin is also part of the primary care protocol in transgender children/youth, and is used in suppressing cis-sex puberty, until the patient is ready to begin cross-sex hormonal therapy.<ref>{{Cite web|title = Primary Care Protocol for Transgender Patient Care: Hormone Administration|url = http://transhealth.ucsf.edu/trans?page=protocol-hormones|website = transhealth.ucsf.edu|accessdate = 2015-09-29|archiveurl = https://web.archive.org/web/20120117030324/http://www.transhealth.ucsf.edu/trans?page=protocol-hormones|archivedate = 2012-01-17|dead-url=no}}</ref>

==Adverse effects==
Side effects are mainly due to low testosterone levels and include headache, [[hot flashes]], reduced [[libido]], and [[erectile dysfunction]].<ref>[[Drugs.com]]: Histrelin {{drugs.com|monograph|histrelin}}</ref>

==Pharmacology==
In a process known as [[downregulation]], daily stimulation of pituitary gonadotropes causes them to become [[Desensitization (medicine)|desensitized]] to the effects of histrelin. As a consequence, levels of [[luteinizing hormone|LH]] and [[follicle-stimulating hormone|FSH]] fall after a short period of time. From that point forward, as long as histrelin is administered, the levels of LH and FSH in the blood remain low.<ref name="Mutschler">{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=372–3|isbn=3-8047-1763-2}}</ref><ref>{{cite journal|pmid=8917899|year=1996|author1=Wuttke|first1=W|title=The neurochemistry of the GnRH pulse generator|journal=Acta neurobiologiae experimentalis|volume=56|issue=3|pages=707–13|last2=Jarry|first2=H|last3=Feleder|first3=C|last4=Moguilevsky|first4=J|last5=Leonhardt|first5=S|last6=Seong|first6=J. Y.|last7=Kim|first7=K|url=http://www.ane.pl/linkout.php?vol=56&no=3&fpp=707}}</ref>

This prolonged lowering of LH and FSH levels is the rationale for therapy using GnRH agonists. Since LH and FSH stimulate the [[gonad]]s to produce [[estrogen]]s and [[androgen]]s in females and males respectively, histrelin can effectively be used to decrease the [[sex steroid]]s in the blood of patients.

==References==
{{Reflist|2}}

== External links ==
* [http://www.supprelinla.com/aboutcpp/index.html Central Precocious Puberty] 


{{Gonadotropins and GnRH}}
{{Peptidergics}}

[[Category:GnRH agonists]]
[[Category:Transgender and medicine]]